Data / Federal awards / NAICS 325412 / RAFA LABORATORIES LTD
RAFA LABORATORIES LTD: 3 federal contract awards, $47.1 million obligated (FY2024 to FY2027)
RAFA LABORATORIES LTD (UEI CKDNTKNDPMJ6), Jerusalem, Israel, received 3 federal prime contract awards with $47.1 million obligated in fiscal years 2024 to 2027, from 1 agency under 2 NAICS codes. Its largest buyer is Department of Health and Human Services ($47.1 million) and its largest code is NAICS 325412 Pharmaceutical Preparation Manufacturing.
SpecStream is the live web data engine for teams and agents. It reads every federal contract award on USAspending.gov and every open opportunity on SAM.gov, and this page is that reading. Ask for the awards in your niche and the winners, agencies, values and recompetes arrive in your sheet, CRM, Slack or agent as they are reported.
- UEI
- CKDNTKNDPMJ6
- Location
- Jerusalem, Israel
- Business size
- Other Than Small Business
- Contract awards
- 3
- Obligated
- $47.1 million
- First action in window
- 2024-08-14
- Latest action
- 2026-08-10
Where the work is
NAICS codes, with the other winners in each.
| NAICS | Industry | Awards | Obligated |
|---|---|---|---|
| 325412 | Pharmaceutical Preparation Manufacturing | 1 | $33.4 million |
| 541714 | Research and Development in Biotechnology (except Nanobiotechnology) | 2 | $13.7 million |
Buying agencies
| Agency | Awards | Obligated |
|---|---|---|
| Department of Health and Human Services | 3 | $47.1 million |
Obligations by fiscal year
| Fiscal year | Obligated |
|---|---|
| FY2024 | $0 |
| FY2025 | $34.4 million |
| FY2026 | $12.7 million |
Contract awards
All 3 awards in fiscal years 2024 to 2027.
| Award ID | Agency | Type | NAICS | What it buys | Obligated in window | Award value | Starts | Ends | Place of performance | Source |
|---|---|---|---|---|---|---|---|---|---|---|
| 75A50325C00020 | Department of Health and Human Services | Definitive Contract | 325412 | RAFA ATROPINE AUTO-INJECTORS (0.5 MG, 1 MG, AND 2 MG) | $33,392,937 | $33,392,937 | September 30, 2025 | September 29, 2027 | Israel | usaspending.gov |
| 75A50125C00018 | Department of Health and Human Services | Definitive Contract | 541714 | THE SCOPE OF WORK FOR THIS CONTRACT INCLUDES THE FOLLOWING DEVELOPMENT ESSENTIALS: CMC DEVELOPMENT, PRE-CLINICAL AND CLINICAL STUDIES, DEVIC | $11,997,762 | $11,997,762 | September 29, 2025 | December 31, 2028 | Israel | usaspending.gov |
| 75A50123C00055 | Department of Health and Human Services | Definitive Contract | 541714 | THE OVERALL OBJECTIVE OF THIS CONTRACT IS TO ADVANCE THE DEVELOPMENT, INCLUDING U.S. FOOD AND DRUG ADMINISTRATION (FDA) APPROVAL, OF ATROPIN | $1,670,282 | $9,371,145 | September 19, 2023 | August 4, 2028 | Israel | usaspending.gov |
Also on SpecStream
- All recipients under NAICS 325412 Pharmaceutical Preparation Manufacturing
- All recipients under NAICS 541714 Research and Development in Biotechnology (except Nanobiotechnology)
- Open opportunities under NAICS 325412
- Open opportunities under NAICS 541714
Updated October 6, 2026. Read from USAspending.gov. Public U.S. federal spending data (U.S. Department of the Treasury). Obligations are the contract actions dated in fiscal years 2024 to 2027 of the USAspending.gov award archive of 2026-10-06; a contract's total value is its current value as USAspending reports it, including earlier years. Recipients are matched on their SAM.gov UEI, never on the name, and are shown as the government prints them. Sole proprietorships and opted-out entities count in the totals and are not named. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.